Cartilage Restoration denied as duplicate or overlapping therapy by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for cartilage restoration are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Blue Cross Blue Shield Issues a Duplicate-Therapy Denial for Cartilage Restoration

Cartilage restoration procedures — which may include techniques such as autologous chondrocyte implantation, osteochondral grafting, or related biologics-based approaches — are sometimes denied by BCBS as "duplicate therapy" when the patient has previously received, or is concurrently authorized for, another cartilage or joint treatment for the same joint. This denial category is also triggered when a claim for a cartilage restoration product or procedure is submitted alongside a claim for a different joint procedure targeting the same anatomic site, and BCBS's claims-processing system flags the combination as redundant.

## Why This Denial Is Appealable

Duplicate-therapy denials are often the result of automated claim-editing rather than clinical review. The clinical reality for cartilage injuries is that staged procedures — an initial mechanical intervention followed later by a biologic restoration approach — are recognized treatment pathways, not redundant ones. If the two procedures address different tissue types, different stages of care, or were performed at different time points for clinically distinct reasons, the duplicate label is incorrect and the denial should be reversed.

## Federal Appeal Framework

• Internal appeal: File within the Explanation of Benefits deadline. Clearly explain the clinical relationship (or non-relationship) between the procedures in question.
• Expedited review: Available if delay would cause serious harm to joint function or health.
• External Independent Review (ACA §2719): Available after internal exhaustion; binding on the plan.
• ERISA §503: Full-and-fair review for employer-sponsored plans; external-review window is approximately four months from denial.

## Documentation to Gather

1. Operative reports for all procedures — detail what was done, to which specific anatomic location, and the clinical indication for each. 2. Imaging — MRI or other imaging confirming the lesion(s) treated by each procedure are distinct, or that the second procedure addresses a different stage of repair. 3. Treating surgeon's letter — a letter explaining why both procedures were medically necessary, why they are not clinically redundant, and how they fit the recognized treatment pathway for this patient's cartilage pathology. 4. Applicable guideline reference — citation to the applicable professional society guideline supporting staged or combined cartilage management. 5. Claim detail — obtain the exact claim lines and procedure codes BCBS flagged; confirm they are correctly coded and that the anatomic-site modifiers are accurate.

## Criteria-Mapping Structure

Obtain BCBS's duplicate-therapy or claim-editing policy for cartilage procedures. In your appeal table, left column: each criterion BCBS used to flag the claim as duplicate; right column: the operative note, imaging finding, or clinical fact that demonstrates the procedures are clinically distinct. Correct any coding errors before resubmitting; include a corrected claim as an exhibit if applicable.